Investing in solid dividend stocks can help navigate the uncertain economic environment we face. Regular payouts can help ...

Amgen (AMGN) stock is in focus as its cholesterol drug Repatha succeeds in a Phase 3 trial, reducing the risk of major ...

Amgen (AMGN) is eyeing the obesity drug race, currently dominated by Eli Lilly (LLY) and Novo Nordisk (NVO), with its two late-stage weight-loss drug trials. Citi Research managing director Geoff ...

Hours after President Donald Trump imposed 100% tariffs on pharmaceuticals with exemptions for companies building manufacturing plants in the U.S., Eli Lilly (NYSE:LLY) and Amgen (NASDAQ:AMGN) ...

Amgen Inc.'s healthy commercial product portfolio and pipeline position the company well for long-term value creation. Read ...

Small and large drugmakers alike have made big, proactive moves to secure the production capacity that will be vital to serving the weight loss market. The scale of the obesity opportunity is ...

“Amgen’s takeaway is simple yet profound: The current system is working, and innovation is benefiting actual patients.” The ongoing policy debate about pharmaceutical and biologic patents has been ...

The Dow Jones Industrial Average is climbing Friday morning with shares of Apple and Amgen leading the way for the price-weighted average. Supported by world-class markets data from Dow Jones and ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended extending the therapeutic indication of Amgen Inc.’s (NASDAQ:AMGN) Uplizna (inebilizumab) to include the ...

Novo Nordisk NVO announced positive data from a sub-analysis of its phase III REDEFINE 1 study assessing the efficacy and safety of once-weekly cagrilintide 2.4 mg as a monotherapy, alongside ...